ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Exploring Clinical Pathways to a Metastatic Lung Cancer Diagnosis: A Latent Class Analysis Using North Carolina Multipayer Claims Data.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC) is the leading cause of cancer mortality in the United States and North Carolina (NC), accounting for more than 5,600 deaths annually in NC. Nearly half of patients are diagnosed with metastatic disease, and the 5-year survival rate is 12%. This study identified clinical pathways preceding the diagnosis of metastatic NSCLC using the North Carolina Central Cancer Registry (NCCCR) linked with multipayer utilization data.
methodsWe identified individuals diagnosed with de novo metastatic NSCLC between 2015 and 2019 in the NCCCR and linked them to claims-based enrollment and utilization files. Latent class analysis examined prediagnostic healthcare encounters, including ambulatory visits, hospitalizations, emergency/urgent department visits, lung cancer screening, and specialist visits, using International Classification of Diseases Ninth/Tenth Revision codes. We evaluated demographic and clinical predictors of pathway membership and examined associations between groups and receipt of tumor molecular testing.
resultsAmong 11,613 individuals, four diagnostic pathways emerged: comprehensive healthcare users (12%), emergency care users (24%), primary care-only users (27%), and low healthcare users (37%). Pathway membership was significantly associated with molecular testing. Primary care-oriented users had the highest adoption of comprehensive or individual biomarker testing, whereas emergency-dominant and low-utilization groups had substantially lower rates.
conclusionsAlthough nearly two thirds of patients engaged with the healthcare system before a metastatic NSCLC diagnosis, more than one third had minimal prediagnostic contact. Differences in molecular testing across pathways indicate disparities in access to precision oncology. IMPACT: Interventions tailored to utilization patterns-particularly for low-contact and emergency-based care users-may improve diagnostic equity, biomarker testing, and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.